Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

70.98 -1.09 (-1.51%)

Streaming Delayed Price Updated: 1:43 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Nektar Therapeutics - Common Stock

NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights

March 10, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

March 10, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR

March 10, 2026

From Pomerantz LLP

Via GlobeNewswire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

March 10, 2026

From Schall Law

Via GlobeNewswire

Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims

March 10, 2026

From Grabar Law Office

Via GlobeNewswire

Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NKTR

March 10, 2026

From DJS Law Group

Via Business Wire

NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm

March 09, 2026

From The Schall Law Firm

Via Business Wire

Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their Rights

March 09, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

NKTR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

March 06, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

March 06, 2026

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)

February 01, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma

March 14, 2022

From Bristol Myers Squibb

Via Business Wire

Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy

December 10, 2021

Palm Beach, FL – December 10, 2021 – FinancialNewsMedia.com News Commentary – Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options...

Via FinancialNewsMedia

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.